ImmuCellICCC -1.71%55 PB Ratio is 3.04 as of Jun. 27, 2026, which is 85% above its 10-year median of 1.64. GuruFocus rates ICCC with a GF Score™ of 55/100 and a GF Value™ of $6.82 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,232 Biotechnology companies, ImmuCell ranks worse than 54.14% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), ImmuCell's share price is $9.79. ImmuCell's Book Value per Share for the quarter that ended in Mar. 2026 was $3.22. Hence, ImmuCell's PB Ratio of today is 3.04.
Warning Sign:
ImmuCell Corp stock PB Ratio (=3.04) is close to 10-year high of 3.14.
The historical rank and industry rank for ImmuCell's PB Ratio or its related term are showing as below:
ICCC'
s PB Ratio Range Over the Past 10 Years
Min: 1 Med: 1.64 Max: 3.14
Current: 3.04
During the past 13 years, ImmuCell's highest PB Ratio was 3.14. The lowest was 1.00. And the median was 1.64.
ICCC's PB Ratio is ranked worse than 54.14% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ICCC: 3.04
During the past 12 months, ImmuCell's average Book Value Per Share Growth Rate was -0.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -2.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ImmuCell was 34.80% per year. The lowest was -19.10% per year. And the median was 2.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ImmuCell PB Ratio Related Terms
ImmuCell PB Ratio Historical Data
* Premium members only.
The historical data trend for ImmuCell's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ImmuCell's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuCell PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmuCell's PB Ratio distribution charts can be found below:
* The bar in red indicates where ImmuCell's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
ImmuCell's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ImmuCell (ICCC) has a PB Ratio of 3.04 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ImmuCell and its competitors. This is 85% above median its historical median of 1.64. Over the past decade, ImmuCell's PB Ratio has ranged from 1.00 to 3.14. According to the industry distribution chart, ImmuCell ranks #667 out of 1232 companies in the Biotechnology industry, placing it in the top 54.1%.
Is ImmuCell's PB Ratio too high?
ImmuCell's current PB Ratio of 3.04 is 85% above median its 10-year median of 1.64. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 3.14. The Biotechnology industry median PB Ratio is 2.80. ImmuCell's value of 3.04 is 8.6% above this industry median. Based on the distribution chart, ImmuCell ranks #667 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ImmuCell has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's PB Ratio compare to NRXS and PTHS?
According to the Biotechnology industry distribution chart, ImmuCell ranks #667 out of 1232 companies for PB Ratio. This places ImmuCell in the lower half of its industry. The industry median PB Ratio is 2.80. ImmuCell's value of 3.04 is 8.6% above this benchmark. Historically, ImmuCell's own PB Ratio has ranged from 1.00 to 3.14 over the past decade. While the company's 10-year median is 1.64 vs. the industry median of 2.80, ImmuCell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImmuCell's current PB Ratio of 3.04 is 8.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ImmuCell and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmuCell's current PB Ratio is 3.04, which is 85% above median its own 10-year median of 1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.82, compared to a current price of $9.79 — trading 43.5% above its estimated fair value. The current PB Ratio is 3.04, which is 85% above median its 10-year median of 1.64 and 8.6% above the Biotechnology industry median of 2.80. ImmuCell's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ImmuCell (ICCC), the current PB Ratio is 3.04 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImmuCell (ICCC) Overvalued in 2026?
Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued.
The current stock price of $9.79 is trading 43.5% above its estimated GF Value™ of $6.82.
GuruFocus considers ImmuCell to be Significantly Overvalued.
Key valuation signals for ICCC:
PB Ratio: 3.04 (85% above median its 10-year median of 1.64)
GF Value™: $6.82 vs. price of $9.79 (43.5% above fair value)
Industry Position: 8.6% above the Biotechnology median (#667 of 1232)
No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
55GF Score
Get the complete analysis for ICCC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICCC has been successfully added to your 
